The Autoimmune Disease DEAP-Hemolytic Uremic Syndrome

ABSTRACT

DEAP-HUS (deficiency of CFHR plasma proteins and factor H [FH] autoantibody positive hemolytic uremic syndrome [HUS]) is a new form of HUS characterized by a deletion of genes coding for FH-related proteins and the presence of autoantibodies directed to FH. These disease-associated autoantibodies inhibit FH (CFH) surface binding functions, which results in a defective regulation of the alternative pathway and damage of endothelial cells. Here we describe two representative patients with DEAP-HUS who both developed end-stage renal failure with the background of homozygous deletion of CFHR1 and CFHR3 genes and the presence of FH autoantibodies. Based on the retrospective diagnosis of DEAP-HUS 2 to 12 months after the initial clinical presentation, subsequent immunosuppressive therapy was initiated. The autoantibody titers decreased, and the complement status of the patients improved, as indicated by increased C3 levels. Thus early diagnosis of DEAP-HUS and immunosuppressive treatments are important factors to treat this particular type of HUS.

KEYWORDS

Autoantibodies - DEAP-HUS - CFHR1 - CFHR3

REFERENCES

• 1 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  361(17) 1676-1687
• 2 Skerka C, Licht C, Mengel M et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: indications for a disease spectrum and common pathogenic principles.  Mol Immunol. 2009;  46(14) 2801-2807
• 3 Józsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.  Blood. 2008;  111(3) 1512-1514
• 4 Dragon-Durey M A, Blanc C, Marliot F et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.  J Med Genet. 2009;  46(7) 447-450
• 5 Abarrategui-Garrido C, Martínez-Barricarte R, López-Trascasa M, de Córdoba S R, Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.  Blood. 2009;  114(19) 4261-4271
• 6 Zipfel P F, Edey M, Heinen S et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.  PLoS Genet. 2007;  3(3) e41
• 7 Dragon-Durey M A, Loirat C, Cloarec S et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(2) 555-563
• 8 Lee B H, Kwak S H, Shin J I et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.  Pediatr Res. 2009;  66(3) 336-340
• 9 Le Quintrec M, Zuber J, Noel L H et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome.  Am J Transplant. 2009;  9(5) 1223-1229
• 10 Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children.  Pediatr Nephrol. 2008;  23(11) 1957-1972
• 11 Strobel S, Hoyer P F, Mache C J et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.  Nephrol Dial Transplant. 2010;  25(1) 136-144
• 12 Józsi M, Strobel S, Dahse H M et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.  Blood. 2007;  110(5) 1516-1518
• 13 Oppermann M, Manuelian T, Józsi M et al. The C-terminus of complement regulator factor H mediates target recognition: evidence for a compact conformation of the native protein.  Clin Exp Immunol. 2006;  144(2) 342-352
• 14 Skerka C, Zipfel P F. Complement factor H related proteins in immune diseases.  Vaccine. 2008;  26(Suppl 8) I9-I14
• 15 Zipfel P F, Skerka C. FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function.  Immunol Today. 1999;  20(3) 135-140
• 16 Skerka C, Horstmann R D, Zipfel P F. Molecular cloning of a human serum protein structurally related to complement factor H.  J Biol Chem. 1991;  266(18) 12015-12020
• 17 Skerka C, Kühn S, Günther K, Lingelbach K, Zipfel P F. A novel short consensus repeat-containing molecule is related to human complement factor H.  J Biol Chem. 1993;  268(4) 2904-2908
• 18 Skerka C, Hellwage J, Weber W et al. The human factor H-related protein 4 (FHR-4). A novel short consensus repeat-containing protein is associated with human triglyceride-rich lipoproteins.  J Biol Chem. 1997;  272(9) 5627-5634
• 19 Józsi M, Richter H, Löschmann I et al. FHR-4A: a new factor H-related protein is encoded by the human FHR-4 gene.  Eur J Hum Genet. 2005;  13(3) 321-329
• 20 Skerka C, Timmann C, Horstmann R D, Zipfel P F. Two additional human serum proteins structurally related to complement factor H. Evidence for a family of factor H-related genes.  J Immunol. 1992;  148(10) 3313-3318
• 21 McRae J L, Cowan P J, Power D A et al. Human factor H-related protein 5 (FHR-5). A new complement-associated protein.  J Biol Chem. 2001;  276(9) 6747-6754
• 22 Venables J P, Strain L, Routledge D et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene.  PLoS Med. 2006;  3(10) e431
• 23 Heinen S, Hartmann A, Lauer N et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.  Blood. 2009;  114(12) 2439-2447
• 24 Zipfel P F, Skerka C. Complement regulators and inhibitory proteins.  Nat Rev Immunol. 2009;  9(10) 729-740
• 25 Ståhl A L, Kristoffersson A, Olin A I et al. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome.  Mol Immunol. 2009;  46(11-12) 2236-2243